Lactate signal in ALS gains momentum as a pragmatic biomarker
New findings indicate that a routine blood measure—lactate—tracks with physical outcomes in amyotrophic lateral sclerosis (ALS), with lower levels linked to weight loss and a poorer prognosis. The research team monitored patients in Japan and Australia and reports that individuals with low blood lactate began losing weight progressively within three months. The study, led by collaborators spanning Shiga University of Medical Science and the Australian Institute for Bioengineering and Nanotechnology, has been published in Annals of Neurology.
“Lactate is an essential metabolic fuel and has long been known to influence motor neuron survival,” Dr Ryutaro Nakamura said. “This includes supporting the metabolic demands associated with ALS.”
“Simply put, the more lactate an ALS patient has in their blood, the more likely they are to maintain weight and have a better prognosis.”
“Our findings support the hypothesis that lower lactate levels are associated with an increased likelihood of weight loss in ALS patients, faster disease progression and earlier death,” Associate Professor Shyuan Ngo said.
“Including both Australian and Japanese patients shows that the correlation between blood lactate levels, weight loss, and ALS prognosis transcends race and environment,” Dr Nakamura said.
“Because weight loss strongly predicts survival in ALS, patients with low lactate levels may benefit from early and intensive nutritional support to improve outcomes,” Dr Nakamura said.
Study snapshot from a binational ALS cohort
- Geography and setting: Japan and Australia, spanning academic ALS clinics and research institutes, with patients followed in routine neuromuscular care settings.
- Participants: 146 people with ALS monitored longitudinally from diagnosis through subsequent clinic visits.
- Key measurement: Serial blood lactate levels as a metabolic readout, obtained using standard clinical chemistry assays already in widespread use.
- Observed outcomes:
- Low lactate levels were followed by progressive weight loss after 3 months.
- Lower lactate associated with faster disease progression and earlier death.
- Interpretation: Lactate functions as a prognostic biomarker candidate in ALS, capturing aspects of the disease’s metabolic burden. The authors stress that the findings are associative rather than causal and that lactate should be evaluated alongside, not instead of, existing clinical scales.
- Publication and institutional details: Full report in a peer‑reviewed neurology journal, with institutional materials available from The University of Queensland.
Why lactate matters in ALS care pathways
Lactate is a ubiquitous, low‑cost clinical analyte that reflects shifts in cellular metabolism. In ALS, growing evidence points to energy dysregulation across motor neurons and peripheral tissues, with weight loss and hypermetabolism emerging as strong predictors of survival. A readily obtainable biomarker that correlates with weight trajectory—a powerful predictor of survival—could help clinicians and health systems anticipate risk and plan supportive care more effectively.
Because venous lactate can be added to existing blood panels without new equipment, the signal described in this study offers a potentially scalable way to flag patients whose weight and functional status may deteriorate quickly, complementing established tools such as ALS functional rating scales and respiratory assessments.
| Clinical or system need | What lactate measurement could offer | Operational considerations |
|---|---|---|
| Early identification of patients at risk of rapid decline | Prognostic stratification tied to weight maintenance and survival signals, informing earlier conversations about feeding support and mobility aids. | Standardized timing of draws; integration with visit schedules and ALS registries so that lactate trends can be reviewed alongside functional scores. |
| Nutritional and metabolic management planning | Trigger for intensified, multidisciplinary nutrition support and monitoring, particularly for patients with declining lactate levels and emerging weight loss. | Coordination with dietitians; documentation for care plans and outcomes tracking within existing multidisciplinary ALS pathways. |
| Clinical trial enrichment | Stratification variable to balance metabolic risk across arms, reducing confounding by unrecognized hypermetabolism or rapid weight loss. | Protocolized thresholds; pre‑specified analyses; data sharing standards that allow lactate to be harmonized across sites and sponsors. |
| Health‑system resource allocation | Risk‑aligned follow‑up cadence and home‑based monitoring prioritization for patients with low or falling lactate levels. | Pathway updates within multidisciplinary ALS clinics and telehealth programs, including criteria for when to escalate dietetic, respiratory, or palliative input. |
Regulatory and implementation context
- Laboratory readiness: Lactate assays are already routine in hospital and ambulatory laboratories. In the United States, testing is delivered under Clinical Laboratory Improvement Amendments (CLIA) certification within existing quality frameworks, enabling rapid uptake without new device approvals if clinicians elect to use lactate for ALS risk stratification.
- Clinical governance: Positioning lactate as a prognostic biomarker for ALS will require professional‑society guidance on test frequency, interpretation with other markers (for example, neurofilament light chain), and documentation standards in electronic health records, particularly if lactate‑based risk tiers are used to trigger changes in visit frequency or access to nutrition services.
- Payment and coverage: Because lactate is a standard, low‑cost test, payer policies are unlikely to present major barriers; however, formal use as a risk‑stratifier may prompt updates to care‑management benefits, prior‑authorization criteria for high‑intensity nutritional support, and quality metrics in public and private plans.
- Equity: Simple, inexpensive biomarkers can reduce disparities if paired with access to dietetic support, respiratory assessment, and assistive technology—core services in multidisciplinary ALS care. Without parallel investment in these services, there is a risk that earlier identification of high‑risk patients simply documents, rather than narrows, outcome gaps.
Placing the findings within the broader evidence base
Beyond critical care and trauma—where lactate has long served as a marker of physiologic stress—neurologic research is increasingly linking metabolic signals to outcomes. In ALS, the present study extends this paradigm to a disease where energy imbalance and weight loss carry outsized prognostic weight. Notably, the lactate signal was observed across two national cohorts, supporting generalizability and underscoring the feasibility of using a standardized, widely available test in routine neuromuscular clinics.
- Health outcomes highlighted by the study:
- Probability of weight maintenance linked to higher blood lactate in people living with ALS.
- Association between lower lactate, faster progression, and earlier mortality, reinforcing the central role of metabolic reserve in ALS trajectories.
- Next validation steps for systems and researchers:
- Define data‑driven thresholds and trajectories (single value vs. kinetics) for risk tiers that clinicians and payers can interpret consistently.
- Evaluate how lactate adds to existing prognostic models when combined with functional scales, respiratory metrics, and other biomarkers.
- Test whether stratification by lactate improves trial efficiency or care‑planning outcomes at scale, including whether it can help health systems prioritize early nutritional and palliative interventions for those at highest metabolic risk.
For policymakers and institutional leaders, the signal emerging from this binational cohort is less about a new test than about a new way to use an old one—repurposing a familiar laboratory measure to bring earlier structure, and potentially greater equity, to ALS care.
